Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Anticoagulation service improves quality of care for patients treated with warfarin

A pharmacist-directed anticoagulation service improves the coordination of care from the hospital to an outpatient clinic for patients treated with the anticoagulant drug warfarin, according to a Henry Ford Hospital study.

11 Aug 2011

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.

10 Aug 2011

GenMark Diagnostics second quarter revenues increase to $901,000

GenMark Diagnostics, Inc. today reported financial results for the second quarter ended June 30, 2011.

5 Aug 2011

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

The Guidelines Department of the European Society of Cardiology has issued the following statement today: "The European Society of Cardiology (ESC) is aware of the early termination of the PALLAS trial because of adverse outcomes associated with dronedarone.

5 Aug 2011

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study was initiated at Colorado Heart & Vascular, P.C. in Denver and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

30 Jul 2011

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease.

25 Jul 2011

Humans' desire to kill rats has only made them stronger

Over millennia, mice have thrived despite humanity's efforts to keep them at bay. A Rice University scientist argues some mice have found two ways to achieve a single goal -- resistance to common poison.

22 Jul 2011

Drug labels sometimes lack key safety warnings: Consumer Reports Health

It's comparable to driving a car without a seatbelt—a new investigation from Consumer Reports Health finds that drug labels sometimes lack key safety warnings and some pharmacies fail to include the medication guides required by the federal government.

28 Jun 2011

On-X LTI announces four clinical trial results of Prosthetic Heart Valve

On-X Life Technologies, Inc. announced today that four clinical trial reports, documenting the On-X Prosthetic Heart Valve's extraordinary performance, will be presented at the upcoming meeting of the Society for Heart Valve Disease in Barcelona, Spain being held June 25-28, 2011.

28 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

Rheonix, Mayo Clinic partner for genotyping test to assist warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings.

21 Jun 2011

Mayo Clinic announces collaboration on genotyping test for Warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, to clients throughout the world.

20 Jun 2011

GenMark prices public offering of common stock

GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing proprietary eSensor detection technology, announced today the pricing of a public offering of 7,065,600 shares of its common stock at a price to the public of $4.25 per share.

17 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

Experts from medical and patient communities call on national policymakers in the Asia-Pacific region to take urgent action against preventable strokes that strike millions of people with atrial fibrillation each year.

7 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Warfarin News and Research

Further Reading

Anticoagulation service improves quality of care for patients treated with warfarin

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

GenMark Diagnostics second quarter revenues increase to $901,000

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Humans' desire to kill rats has only made them stronger

Drug labels sometimes lack key safety warnings: Consumer Reports Health

On-X LTI announces four clinical trial results of Prosthetic Heart Valve

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Rheonix, Mayo Clinic partner for genotyping test to assist warfarin sensitivity

Mayo Clinic announces collaboration on genotyping test for Warfarin sensitivity

GenMark prices public offering of common stock

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News